The present application provides liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides. The present application also provides nanodiamond complexes and particles as carriers for anti-cancer agents.

Disclosed herein are nanostructures, compositions, and methods for treating ocular disorders, injuries, and infections using RNA complexed nanoparticles (e.g., RNA-templated lipoprotein particles, miRNA-high density lipoprotein particles). These nanostructures are contemplated in topical therapies.

Compositions and methods for synthesis of protein stabilized liposomes (PSLs) is described. In one aspect, a protein excipient that stabilizes liposome integrity, when incorporated into liposome formulations, is provided. The manufacturing process for production of metastable liposome particles with a half-life of several months is also described. In some aspects the liposome particles may contain a bioactive agent. In some cases, the bioactive agent is a protein, nucleic acid, lipid, or small molecule.

Disclosed herein are MDSC-targeted extracellular vesicles (EVs) loaded with therapeutic cargo, as well as compositions, systems, and methods for making same. Also disclosed herein is an MDSC-targeting ligand, such as a fusion protein containing an MDSC-targeting moiety. Also disclosed are EVs containing the disclosed fusion protein. In some embodiments, the EV is also loaded with a therapeutic cargo. Also disclosed is an EV-producing cell engineered to produce the disclosed EVs. Also disclosed is a method for making the disclosed EVs that involves culturing the disclosed EV-producing cells under conditions suitable to produce EVs.

The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.

Nanostructures for the systemic delivery of nucleic acids, such as RNA, are provided herein. The nanostructures include templated lipoprotein nanoparticles (TLPs) composed of a core decorated with proteins, a lipid bilayer and hydrophobic molecules that self-assemble with nucleic acids, such as RNA. The nanostructures are useful for research, therapeutic and diagnostic applications.

The present invention relates to vaccine compositions based on Gram-negative outer membrane vesicles displaying antigens of pathogens expressed as part of a fusion protein comprising N-terminal parts of surface expressed lipoproteins of Gram-negative bacteria, and use of such compositions in vaccination. The invention further relates to the fusion lipoproteins comprising N-terminal parts of surface expressed lipoproteins of Gram-negative bacteria and antigens of pathogens fused thereto, DNA constructs and bacterial host cells for expressing these fusion lipoproteins and to methods for producing outer membrane vesicles displaying the fusion lipoproteins.

Lipid-based delivery vehicles are provided. Nanoparticulate compositions typically including a p21 activated kinase (PAK) inhibitor and a lipid-based delivery vehicle are also provided. In preferred embodiments, the lipid-based delivery vehicle is a liposome, most preferably a sterically-stabilized liposome. Typically the lipid-based delivery vehicle includes one or more phospholipids, and optionally a sterol. In some embodiments, at least one of the phospholipids is PEGylated. In particular embodiments, the lipid-based delivery vehicle includes DSPC, DSPE-PEG2000, and cholesterol. In specific embodiments, the ratio of DSPC, DSPE-PEG, and cholesterol is 9:1:5. The nanoparticulate composition typically includes a PAK inhibitor, preferably a PAK-1 inhibitor such as IPA-3 or a derivative, prodrug, or pharmaceutically acceptable salt thereof. Methods of use, for example methods of treating cancer, particularly prostate and breast cancer by administering the composition to subjects in need thereof, are also provided.

The present invention discloses targeting microRNAs as a potential therapeutic target for cancer, more particularly glioblastoma (GBM). It discloses targeting microRNAs with gold-nanoliposomes labeled with brain targeting-peptides inducing a significant cell growth arrest and inhibition of miRNA-92b, an aberrantly abundant miRNA found in GBM cells. Furthermore, it delivers gold-nanoliposomes to the brain by crossing the blood brain barrier (BBB) and reaching cancer tumors.

The invention provides a compartmentalised gel matrix comprising one or more compartments, wherein each compartment comprises a volume of hydrophobic medium and one or more aqueous droplets therein. The invention further provides a pharmaceutical formulation comprising a compartmentalised gel matrix according to the invention, a synthetic cell comprising a compartmentalised gel matrix according to the invention and a synthetic tissue comprising a compartmentalised gel matrix according to the invention.